Although they found that MDS and CMML patients exhibiting SETBP1 mutations had significantly worse prognosis than their wild-type counterparts, there was—similar to Elliott et al.’s findings18—no significant effect of SETBP1 mutations on prognosis in CNL, though both these studies were limited by relatively small sample sizes136. This evidence concerns the gene SETBP1 and chronic myelomonocytic leukemia.